

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先 健 科 技 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

CHANGE OF DIRECTORS AND COMPOSITION OF BOARD COMMITTEES

The board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of LifeTech Scientific Corporation (the “**Company**”, and together with its subsidiaries, the “**Group**”) hereby announces that with effect from 21 November 2025:

- (i) Ms. RUAN Xingmei (“**Ms. Ruan**”) has resigned as an executive Director of the Company (the “**Executive Director**”) and a member of the nomination committee of the Company (the “**Nomination Committee**”);
- (ii) Mr. LIANG Hsien Tse Joseph (“**Mr. Liang**”) has resigned as an independent non-executive Director of the Company (the “**Independent Non-executive Director**”), chairman of the audit committee of the Company (the “**Audit Committee**”) and a member of each of the Nomination Committee and the remuneration committee of the Company (the “**Remuneration Committee**”);
- (iii) each of Ms. WU Liping (“**Ms. Wu**”) and Mr. FANG Yu (“**Mr. Fang**”) has been appointed as an Executive Director;
- (iv) Ms. FENG Xiaoling (“**Ms. Feng**”) has been appointed as an Executive Director and a member of the Nomination Committee; and
- (v) Ms. CHEN Dongxia (“**Ms. Chen**”) has been appointed as an Independent Non-executive Director, chairlady of the Audit Committee and members of the Nomination Committee and Remuneration Committee.

RESIGNATION OF AN EXECUTIVE DIRECTOR

The Board has received a letter of resignation from Ms. Ruan whereby she tendered her resignation as Executive Director and her position as a member of the Nomination Committee with effect from 21 November 2025 in order to devote more time to her core business areas and other endeavors. The Board believes that Ms. Ruan's resignation should not have adverse impact on the operations of the Group as she will continue to serve as the Chief Compliance Officer and Deputy Finance Director of the Group and also as the supervisor and financial person-in-charge of various subsidiaries and associates of the Group.

Ms. Ruan confirmed that she has no disagreement in any aspect with the Company or the Board and there are no matters in relation to her resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). The Board would like to express its sincere appreciation to Ms. Ruan for her valuable contribution to the Company during her tenure as Executive Director.

RESIGNATION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board has received a letter of resignation from Mr. Liang whereby he tendered his resignation as Independent Non-executive Director and his positions as chairman of the Audit Committee and a member of each of the Nomination Committee and Remuneration Committee with effect from 21 November 2025 in order to meet the requirements of the Stock Exchange in relation to long-serving Independent Non-executive Directors who have served for more than nine years.

Mr. Liang confirmed that he has no disagreement in any aspect with the Company or the Board and there are no matters in relation to his resignation that need to be brought to the attention of the Shareholders or the Stock Exchange. The Board would like to express its sincere appreciation to Mr. Liang for his valuable contribution to the Company during his tenure as Independent Non-executive Director.

APPOINTMENT OF EXECUTIVE DIRECTORS

The Board hereby announces that with effect from 21 November 2025, each of (i) Ms. Wu and Mr. Fang has been appointed as an Executive Director; and (ii) Ms. Feng has been appointed as an Executive Director and a member of the Nomination Committee.

Ms. WU Liping, aged 45, holds a bachelor's degree and is currently pursuing an EMBA at the University of Hong Kong — Peking University. Ms. Wu has been deeply engaged in the field of vascular minimally invasive therapy for over 20 years. Since joining the Group in 2006, she has established the market systems and product portfolio for the aortic and peripheral vascular businesses of the Group. Ms. Wu is currently serving as the vice president of the Group, where she is responsible for the overall operation, management, strategy formulation and execution of the comprehensive pan-vascular business segment. She also holds directorships, legal representative roles, and senior management positions in several of the Group's subsidiaries and joint ventures.

During her tenure, Ms. Wu spearheaded the research and development, clinical registration, market access, and commercialisation strategies for multiple innovative medical devices. She has been instrumental in driving the transformation of the Group's aortic business from a single-product focus towards offering integrated pan-vascular solutions. Ms. Wu has achieved several breakthroughs in aortic endovascular treatment innovations and the commercialisation of domestically developed high-end medical devices. She pioneered the Group's strategic expansion into new pan-vascular sectors, propelling the sustained development and scalable growth of the peripheral vascular business. Concurrently, she accelerated the Group's collaboration and capability building in industry-academia-research initiatives, leading synergistic partnerships with numerous universities and clinical institutions. These efforts have substantially strengthened the Group's foundational capabilities in original product innovation, clinical demand translation, and cross-disciplinary collaboration.

Ms. Wu was awarded the First Prize of the 2024 Chinese Medical Science and Technology Award and the First Prize of the 2024 Military Science and Technology Progress Award. She holds several relevant invention patents and consecutively received the Shenzhen Industrial Development and Innovation Talent Award from 2019 to 2021. She also serves as a committee member of the vascular surgery branch of the Jiangsu Research Hospital Association and acts as an external postgraduate supervisor for the Textiles College of Donghua University.

Mr. FANG Yu, aged 47, holds a bachelor's and master's degree in Polymer Materials Science and Engineering from Tsinghua University. Mr. Fang has over 20 years of experience in the medical device industry. Mr. Fang currently serves as the vice president of the Group, where he is primarily responsible for the overall coordination and strategic execution of the structural heart diseases and electrophysiology business. Mr. Fang also serves as a chairman, director, supervisor, legal representative and senior management of various subsidiaries, associates and joint ventures of the Group. Since assuming his current position in the Group in 2016, he has led the structural heart department to achieve rapid sales growth, spearheaded the comprehensive market launch and promotion of the Group's Left Atrial Appendage

Occluder, and driven improvements and optimisation of existing products while exploring new business areas and incubating new products. Mr. Fang possesses extensive project management expertise and innovation capability, holds several relevant invention patents, and consecutively received the Shenzhen Industrial Development and Innovation Talent Award from 2019 to 2021. Prior to joining the Group, he worked at Johnson & Johnson (Shanghai) Medical Devices Limited and St. Jude Medical (Shanghai) Co., Ltd.

Ms. FENG Xiaoling, aged 54, holds a MBA from the Shanghai University of Finance and Economics and has over 25 years of corporate management experience, with notable achievements in international business expansion. Ms. Feng currently serves as the vice president of the Group, with responsibility for the Group's international market development, cross-border business cooperation, and global resource integration. Ms. Feng also serves as a director, legal representative and senior management of various subsidiaries, associates and joint ventures of the Group. Since joining the Group in 2017, she has successfully led the establishment of an in-depth market network in over 100 countries and regions worldwide, driving the international commercialisation of multiple innovative medical device products. Under her leadership, the Group's international layout has become increasingly robust, with global subsidiaries and offices developing synergistically and the sales network continuously expanding, significantly enhancing the Group's brand influence and competitiveness in the international market. Prior to joining the Group, Ms. Feng held senior executive positions at several multinational corporations.

Save as disclosed in this announcement, each of Ms. Wu, Mr. Fang and Ms. Feng does not hold any other position in the Group and does not have any other major appointments and professional qualifications, and did not hold any directorships in public companies of which the securities are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of his/her appointment. Each of Ms. Wu, Mr. Fang and Ms. Feng does not have any relationship with any Directors, senior management, substantial shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) and controlling shareholders (as defined in the Listing Rules) of the Company.

Each of Ms. Wu, Mr. Fang and Ms. Feng has entered into an appointment agreement with the Company for his/her role as an Executive Director for a term of three years commencing from 21 November 2025, subject to early termination as provided thereunder. Each of Ms. Wu, Mr. Fang and Ms. Feng's tenure as an Executive Director is subject to retirement by rotation and re-election in accordance with the Listing Rules and the articles of association of the Company. Each of Ms. Wu, Mr. Fang and Ms. Feng's monthly emolument for his/her roles in the Group is

RMB155,732, RMB150,053 and RMB140,495, respectively, and discretionary bonus shall be determined based on his/her annual performance assessment. Each of Ms. Wu, Mr. Fang and Ms. Feng is not entitled to any additional emolument for his/her role as an Executive Director.

As at the date of this announcement, (i) Ms. Wu is interested in 100,040,000 shares of the Company (the “**Shares**”) within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”) (by virtue of the 23,040,000 share options and 77,000,000 share awards granted to her) and 35,830,000 Shares; (ii) Mr. Fang is interested in 94,700,000 Shares within the meaning of Part XV of the SFO (by virtue of the 17,700,000 share options and 77,000,000 share awards granted to him) and 31,000,000 Shares; and (iii) Ms. Feng is interested in 95,045,000 Shares within the meaning of Part XV of the SFO (by virtue of the 18,100,000 share options and 76,945,000 share awards granted to her) and 35,605,000 Shares. The aforementioned share options granted to each of Ms. Wu, Mr. Fang and Ms. Feng were granted pursuant to (i) the share option scheme adopted by the Company on 22 October 2011 for a price of HK\$3.57 per Share; and (ii) the share option scheme adopted by the Company on 17 September 2021 for a price of HK\$1.95 and HK\$3.836 per Share (as applicable). The aforementioned share awards granted to each of Ms. Wu, Mr. Fang and Ms. Feng were granted pursuant to the share award scheme of the Company adopted on 28 December 2018 (the “**2019 Share Award Scheme**”) for a price of HK\$1.35 per Share and as at the date of this announcement, such Shares are held by the trustee of the 2019 Share Award Scheme and the exercise price of which has not been settled by each of Ms. Wu, Mr. Fang and Ms. Feng.

Save as disclosed above, there is no other information that is required to be disclosed under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters in relation to the appointments of each of Ms. Wu, Mr. Fang and Ms. Feng as an Executive Director that need to be brought to the attention of the Shareholders or the Stock Exchange.

APPOINTMENT OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board hereby announces that Ms. Chen has been appointed as an Independent Non-executive Director, the chairlady of the Audit Committee and a member of the Remuneration Committee and Nomination Committee with effect from 21 November 2025.

Ms. CHEN Dongxia, aged 49, is a senior professional in financial investment and asset management with over 20 years of experience in cross-border capital operations and merger and acquisition investments. She holds dual bachelor's degrees in Accounting and International Business from Jinan University in China, as well as a master's degree in Accounting and Finance from the University of Sydney in Australia. She also holds professional qualifications including CFA, FCPA, and ESG Investing, and is licensed by the Hong Kong Securities and Futures Commission as a Responsible Officer (RO) for Type 4 (Advising on Securities) and Type 9 (Asset Management) regulated activities.

Ms. Chen is currently the Council Member of the Hong Kong China Financial Association, she served as Deputy General Manager of China Resources Healthcare Group Limited, Deputy General Manager of the Finance Department of China Resources Group, and General Manager of Finance at CR Capital. She has extensive experience in cross-border investments, mergers and acquisitions, and private equity funds, and has led multiple major capital transactions and the establishment and fundraising of various private equity funds.

Ms. Chen is fluent in both Chinese and English, well-versed in diverse capital market environments, and brings both an international perspective and strong localized execution capabilities.

Ms. Chen has entered into an appointment agreement with the Company for her role as an Independent Non-executive Director for a term of three years commencing from 21 November 2025, subject to early termination as provided thereunder and to retirement by rotation and re-election in accordance with the Listing Rules and the articles of association of the Company. Under the aforesaid letter of appointment, Ms. Chen will receive a director's fee of RMB180,000 per annum. The remuneration of Ms. Chen has been determined with reference to the prevailing market conditions, her role and responsibilities and the Company's remuneration policy. Such remuneration has been recommended by the Remuneration Committee and approved by the Board and will be reviewed by the Remuneration Committee and the Board on an annual basis.

As at the date of this announcement, save as disclosed above, Ms. Chen has confirmed that she (i) does not hold any other position in the Company or any its subsidiaries, nor served as a director of any public company with securities listed on any securities market in Hong Kong or overseas in the past three years and does not have other major appointments and professional qualifications; (ii) has no relationship with any Director, senior management, substantial shareholder (as defined under the Listing Rules) or controlling shareholder (as defined under the Listing Rules) of the Company; and (iii) did not, and was not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the SFO.

As at the date of this announcement, Ms. Chen has confirmed that (i) she meets the independence requirements as set out in Rule 3.13 of the Listing Rules; (ii) she has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment as an Independent Non-executive Director.

Save as disclosed above, the Board is not aware of any other matters relating to the appointment of Ms. Chen that needs to be brought to the attention of the Shareholders or the Stock Exchange, nor is there any other information which is required to be disclosed by the Company pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

CHANGES IN THE COMPOSITION OF BOARD COMMITTEES

Following the above changes to the Board, with effect from 21 November 2025:

- (i) Ms. Ruan ceased to be a member of the Nomination Committee;
- (ii) Mr. Liang ceased to be the chairman of the Audit Committee and a member of each of the Nomination Committee and Remuneration Committee;
- (iii) Ms. Feng has been appointed as a member of the Nomination Committee; and
- (iv) Ms. Chen has been appointed as the chairlady of the Audit Committee and a member of each of the Nomination Committee and Remuneration Committee.

The Board would like to extend a warm welcome to each of Ms. Wu, Mr. Fang and Ms. Feng for his/her new role as an Executive Director and Ms. Chen for her new role as an Independent Non-executive Director.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 21 November 2025

As at the date hereof, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong, Ms. WU Liping, Mr. FANG Yu and Ms. FENG Xiaoling being executive Directors; Mr. JIANG Feng being non-executive Director; Mr. WANG Wansong, Mr. ZHOU Luming and Ms. CHEN Dongxia being independent non-executive Directors.